Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03373539 · ClinicalTrials.gov registry record
Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 70
- Enrollment target
NCT03373539 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 70 participants.
The verdict
NCT03373539 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 70 participants
- Enrollment target
Study Summary
Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset and development of diseases. Thus, it is crucial to understand the mechanisms that regulate normal development and the pathways that contribute to disease pathogenesis. Neurotrophins are a family of four proteins that support the growth and survival of neurons. Their secretion increases during brain development, when new neurons are being formed and existing ones are branching to assemble complex neuronal circuits. In addition to their role in promoting neuron growth and development, neurotrophins are also a product of neuronal activity. Neurotrophins are also responsible for the maintenance of peripheral sensory neurons, including those in the lungs. Airway innervation is responsible for many aspects of lung function including the regulation of airway smooth muscle tone, mucus secretion, and reactivity; therefore, a physiological expression of neurotrophins in the lungs is required for normal lung function.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03373539
The ClinicalTrials.gov registry entry for NCT03373539 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03373539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03373539 about?
NCT03373539 is a clinical study titled "Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes". Important developmental processes continue until the completion of 40 weeks gestation. Even during fetal life, intrinsic and environmental factors determine the balance between health and the onset and development of diseases. Thus, it is crucial to understand the mechanisms that regulate normal dev...
What is the current status of trial NCT03373539?
This trial is currently completed. The enrollment target is 70 participants. The study started on 2014-12. Estimated completion is 2019-08.
Who is sponsoring clinical trial NCT03373539?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.